About Apricus Bio
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has a strong pipeline of multiple late-stage product opportunities, primarily in the area of sexual health.
Femprox® (alprostadil 0.4% topical cream) is a product candidate for the treatment of female sexual arousal disorder (FSAD). Femprox® is a topical, on-demand route of administration and targets an indication in which no product has been approved in the U.S. to date to treat FSAD, a persistent or recurring inability to attain or maintain adequate sexual arousal.
Our vision is to be a leader in the development and commercialization of innovative products that improve sexual health.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Abbott Laboratories, Sandoz, Warner Chilcott and Bracco.
Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.